These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20228405)

  • 1. ACCORD and Risk-Factor Control in Type 2 Diabetes.
    Nilsson PM
    N Engl J Med; 2010 Apr; 362(17):1628-30. PubMed ID: 20228405
    [No Abstract]   [Full Text] [Related]  

  • 2. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination statin-fibrate therapy: safety aspects.
    Franssen R; Vergeer M; Stroes ES; Kastelein JJ
    Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 5. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Tonkin AM; Chen L
    Circulation; 2010 Aug; 122(8):850-2. PubMed ID: 20733114
    [No Abstract]   [Full Text] [Related]  

  • 7. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 8. [Diabetics' life is about one third shorter. So you improve the prognosis of these high-risk patients].
    Stiefelhagen P
    MMW Fortschr Med; 2003 Apr; 145(15):18, 20. PubMed ID: 15104261
    [No Abstract]   [Full Text] [Related]  

  • 9. [Integrated drug therapy of the metabolic syndrome].
    Julius U; Hanefeld M
    Internist (Berl); 1996 Jul; 37(7):722-30. PubMed ID: 8766266
    [No Abstract]   [Full Text] [Related]  

  • 10. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 11. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 13. [Normalization of blood pressure and lipids in patients with diabetes].
    Clemens A; Gallwitz B
    Med Klin (Munich); 2003 Jul; 98(7):368-76. PubMed ID: 12937902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting of the minds. Should pre-hypertension in type 2 diabetes be treated?
    Bihl G; Amod A; Ellis G; Moore R; Raal FJ; Gernholtz T; Schamroth C; Horak A
    Cardiovasc J Afr; 2010; 21(3 Suppl):S9-S13. PubMed ID: 20532426
    [No Abstract]   [Full Text] [Related]  

  • 15. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introductory remarks.
    Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R
    Am J Ther; 2010; 17(3):236. PubMed ID: 20479578
    [No Abstract]   [Full Text] [Related]  

  • 17. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 18. Brief comments on the issue of cardiovascular risk in diabetic patients.
    Lasaridis AN
    Am J Hypertens; 2004 Jul; 17(7):640. PubMed ID: 15233987
    [No Abstract]   [Full Text] [Related]  

  • 19. [Success of blood pressure reduction in diabetic patients].
    Schernthaner G
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S247-51. PubMed ID: 17139580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of cardiovascular disease in type 2 diabetic patients].
    Yokota C
    Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.